Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2000

View Archived Issues

Evotec founds Direvo Biotech

Medi-Ject and Permatec to combine drug delivery business

Valtaxin approved in Canada for CIS of the bladder

Millennium reports progress in Q2 2000

Vivus accelerates R&D efforts during second quarter

Gene for primary pulmonary hypertension exclusively licensed to United Therapeutics

Titan acquires novel agent for the treatment of cancer and viral disease

Rapid thrombolysis without reocclusion following acute bolus administration of novel modified t-PA

Substance from spider venom is first to block stretch-activated channels

Abbott reports growing pipeline and accelerated growth

U.K. launch announced for Zyban

AM-424: safety and pharmacokinetics in healthy volunteers following single doses

Z-338 characterized for pharmacokinetics and safety after single and multiple doses

Combination therapy with G-3139 and dacarbazine as new approach to malignant melanoma

Anticonvulsant activity of NW-1015 assessed in primate model

GH secretagogue examined for potential proarrhythmic effects

New hepatitis C treatment reaches market simultaneously in two European countries

Anadys established to develop novel antiinfective agents

Telithromycin at standard and high doses does not prolong Q-T interval in humans

Neuroprotective effects described for SB-269970

Fibrate/statin combinations claimed in recent patent literature by Bayer

Antisense compounds that modulate TNF-alpha-induced expression of cell adhesion molecules

Yeda presents new agents for PDT of tumors

Novel conjugates for inducing tolerance in xenotransplantation

RTI investigators design novel class of potent antiprogestational compounds

Numerous antiherpesvirus agents in development at AHP

Licensing opportunity from Immunex: interleukin-15 (IL-15)

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...